A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Date publication

juin 2026

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Benallegue N, Rollot F, Iaffaldano P, Lucisano G, Simone M, Lugaresi A, Casey R, Cocco E, Vukusic S, De Luca G, Mathey G, Patti F, Maillart E, Amato MP, Michel L, Fantozzi R, Ciron J, De Robertis F, De Sèze J, Coniglio MG, Ruet A, Filippi M, Labauge P, Crisafulli SG, Zephir H, Ferraro D, Papeix C, Lebrun-Frenay C, Trojano M, Laplaud DA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42226562

Résumé

Early initiation of high-efficacy therapies (HETs) has been associated with improved disease control in pediatric-onset multiple sclerosis (POMS). However, some children remain clinically stable on low-/moderate-efficacy therapies (METs), highlighting the need for decision-support tools.

Mots clés

Multiple sclerosis, adolescent, child, prognostic model, real-world data, risk prediction, treatment escalation

Référence

Mult Scler. 2026 06 1;:13524585261446829